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ORIGINAL INVESTIGATION
Vitamin D status is associated with skin 
autofluorescence in patients with type 2 
diabetes mellitus: a preliminary report
Y H M Krul‑Poel1, R Agca1, P Lips2, H van Wijland3, F Stam1 and S Simsek1,2*
Abstract 
Background: Skin autofluorescence is a non‑invasive measurement of advanced glycation end products (AGE), 
which are suggested to be one of the major agents in the pathogenesis and progression of diabetes related cardio‑
vascular complications. Recently, low vitamin D status has been linked to the progression of type 2 diabetes mellitus 
(T2DM) and cardiovascular disease. The aim of this study is to investigate the association between vitamin D status 
and skin autofluorescence in patients with T2DM.
Methods: In this preliminary report skin autofluorescence was measured non‑invasively with an AGE‑reader in 245 
patients with T2DM treated with lifestyle advice, metformin and/or sulphonylurea‑derivatives. All patients were ran‑
domly assigned to receive either vitamin D 50,000 IU/month or placebo for 6 months.
Results: Skin autofluorescence was significantly higher in patients with a serum 25(OH)D <50 nmol/l compared to 
patients with a serum 25(OH)D >75 nmol/l (2.81 versus 2.41; p < 0.001). Mean serum 25(OH)D was 60.3 ± 23.4 nmol/l 
and was independently associated with skin autofluorescence (β −0.006; p < 0.001). Mean vitamin D increased 
from 60.8 to 103.6 nmol/l in the intervention group, however no effect was seen on accumulation of skin AGEs after 
6 months compared to placebo.
Conclusions: Vitamin D status is independently associated with skin auto fluorescence in patients with well‑con‑
trolled T2DM. No effect was seen on the amount of skin AGEs after a short period of 6 months vitamin D supplemen‑
tation. Further research with longer follow‑up and measurement of circulating advanced glycation end products is 
needed to elucidate the causality of the association.
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Background
One of the chronic consequences of hyperglycaemia is 
the accelerated formation of advanced glycation end 
products (AGEs), which are suggested as one of the major 
pathogenic mechanisms causing end organ damage in 
diabetes [1, 2]. AGEs are formed nonenzymatically by the 
modification of proteins, lipids and nucleic acids by glu-
cose. AGEs are highly reactive pro-inflammatory mole-
cules and accumulate slowly over a persons’ lifetime with 
an estimated lifetime of 15 years [3, 4]. Diabetes mellitus, 
chronic renal failure and aging accelerate the genera-
tion of AGEs [5]. AGEs act by binding to the receptor for 
AGEs (RAGE), which is expressed on neutrophils, T-lym-
phocytes, macrophages and synovial fibroblasts. Upon 
binding of AGE to its receptor the transcription of pro-
inflammatory genes is stimulated, leading to the up-reg-
ulation of endothelial adhesion molecules contributing to 
the development of atherosclerosis [6]. In patients with 
type 2 diabetes mellitus (T2DM) AGEs seem to represent 
inflammatory, oxidative and cumulative metabolic stress 
[3]. Earlier research demonstrated an increased skin 
autofluorescence, as a measure of AGE accumulation, in 
patients with T2DM compared to healthy controls [7]. In 
addition, skin autofluorescence predicts both micro- and 
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macrovascular complications in patients with T2DM, 
and has a strong association with the severity of diabetes-
related complications and mortality [2, 8–14].
Similar to the consequences of AGE accumulation, low 
vitamin D status has been linked to numerous biochemi-
cal and clinical disturbances, including the pathogenesis 
and progression of T2DM and cardiovascular disease 
[15–18]. The prevalence of vitamin D deficiency is high 
worldwide, especially in patients with T2DM compared 
to healthy persons [19, 20]. The underlying mechanism 
explaining the association between vitamin D status, 
T2DM and cardiovascular disease is not clarified yet. 
Earlier data suggest a potential independent role for vita-
min D in the regulation of glucose metabolism in a set-
ting of obese patients [21]. It is known that besides the 
classical role of vitamin D in calcium and bone homeo-
stasis, vitamin D is linked to numerous non-skeletal dis-
eases due to the elucidation that most cells, including 
the pancreatic beta-cells and cardiomyocytes contain 
the vitamin D receptor (VDR), and most of them also 
have the capability to produce the biologically active 
1,25-dihydroxyvitamin D for paracrine functions [22, 23]. 
Experimental studies have established a role for vitamin 
D in T2DM and cardiovascular disease by interacting 
with inflammation, insulin resistance, renin-angiotensin 
system, thrombosis and gene regulation [24–28]. To our 
knowledge no literature is available about the associa-
tion between AGEs and vitamin D status in patients with 
T2DM. Hypothetically, vitamin D may reduce inflamma-
tion, oxidative stress and insulin resistance, and thereby 
reducing the accumulation of AGEs. Interestingly, in 
diabetic rats vitamin D supplementation attenuated 
the deposition of AGEs in the vascular system [29] and 
decreased the diabetic effects on the receptor of AGEs in 
rats [30]. Therefore, the aim of our study is to investigate 
the association between vitamin D status and skin auto 
fluorescence in patients with T2DM.
Methods
We performed a preliminary cross-sectional and longi-
tudinal analysis of 245 patients with T2DM. The patients 
were included between July 2012 and April 2013 in a ran-
domised placebo-controlled trial (“the SUNNY trial”), in 
which the effect of 50,000  IU/month vitamin D supple-
mentation during 6 months versus similar looking placebo 
was examined on glycemic control in patients with T2DM 
[31]. The trial was approved by the Medical Ethics Com-
mittee of North-Holland, the Netherlands. The trial pro-
tocol is described in greater detail elsewhere [32]. In brief, 
adult patients (≥18  years), treated with lifestyle advice, 
metformin or sulphonylurea-derivatives, whether or 
not in combination, were invited for participation in the 
trial. The main exclusion criteria were previous treatment 
with insulin, serum 25-hydroxyvitamin D (25(OH)D) 
<15  nmol/l or >150  nmol/l, hypercalcaemia (serum cal-
cium >2.65  nmol/l), impaired renal function (estimated 
glomerular filtration rate [eGFR] <30  ml/min, meas-
ured by the MDRD formula) urolithiasis, and no signed 
informed consent. Throughout the study no drug altera-
tions regarding hypoglycemic agents and statins, and no 
vitamin D supplements were allowed. Informed consent 
was obtained from all patients before start of the trial.
Outcome measures
Outcome measures were obtained at baseline (immedi-
ately prior to dosing), and after 6 months. The following 
data were collected during the first visit: age, gender, eth-
nicity, social status, diabetes duration, medical history, 
family history of T2DM, medication use, diabetic com-
plications, previous cardiovascular disease, co-morbidity, 
smoking status, alcohol use, diet (especially fish and dairy 
products), physical activity, sun exposure, and season of 
blood collection. Cardiovascular disease was defined as 
coronary artery disease/ischemic heart disease, stroke, 
hypertensive heart disease, aortic aneurysms, cardiomyo-
pathy and peripheral artery disease. Standard anthropo-
metric data (height, weight, waist and hip circumference, 
blood pressure) were obtained from each patient. Venous 
blood collection for serum 25(OH)D, HbA1c, fasting 
blood glucose and insulin, lipid profile, serum calcium, 
albumin, estimated glomerular filtration rate (eGFR) 
and parathyroid hormone (PTH) were collected after 
an overnight fast at 8.00–9.30 am. Serum 25(OH)D was 
measured on an iSYS automated immunoanalyser (IDS 
GmbH, Frankfurt, Germany). All samples are stored at 
−20°C for future research on circulating AGE levels.
Skin autofluorescence
Skin autofluorescence levels were measured with an 
AGE reader (Diagnoptics Technologies B.V., Groningen, 
the Netherlands). This non-invasive method utilizes the 
characteristic fluorescent properties of AGEs, and has 
been validated with specific AGE measurements in skin 
biopsies [33]. Autofluorescence was defined as the aver-
age light intensity per nanometer in the range between 
420 and 600 nm, divided by the average light intensity per 
nanometer in the range between 300 and 420 nm. It was 
expressed in arbitrary units (AU) using the AGE reader 
software. Skin autofluorescence was measured at room 
temperature while patients were in a seated position, 
at the volar side of the lower arm. Measurements were 
not specifically performed in a fasting state. Previous 
research has demonstrated that repeated AGE measure-
ments on 1 day showed an overall Altman error percent-
age <6.0%. Intra-individual seasonal variance showed an 
Altman error percentage <6.0% [33].
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Statistical analysis
All data were analysed using the statistical package 
SPSS software (version 20.0, SPSS Inc, Chicago, IL, 
USA). For the purpose of our study and consistent 
with the widely used cut-off values of vitamin D, the 
patients were stratified into three vitamin D groups: (1) 
serum 25(OH)D: 15–49  nmol/l, (2) serum 25(OH)D: 
50–74 nmol/l, and (3) serum 25(OH)D: 75–150 nmol/l 
[34]. Baseline characteristics were compared using χ2-
test for categorical variables and ANOVA or Kruskal–
Wallis for continuous variables depending on normal 
distribution. Data are presented as mean  ±  standard 
deviation if normally distributed and otherwise as 
median and interquartile range. Multiple linear regres-
sion analysis was used to determine independent 
associations between vitamin D status and skin auto-
fluorescence. We adjusted for confounders based on 
the literature and regression correlation coefficient dif-
ference >10%: age, season of measurement, duration 
of diabetes, renal function, gender, ethnicity, smoking 
behaviour, lipid profile, HbA1c, and the presence of car-
diovascular disease. Linear regression analysis was used 
to assess the mean difference between intervention 
and placebo groups after 6  months (mean difference 
is reported as beta). A p value <0.05 was considered as 
statistically significant.
Results
Baseline skin autofluorescence level was determined in 
245 of 275 patients included in the SUNNY trial. Skin 
autofluorescence was not measurable in 30 patients, 
mainly due to low reflection caused by dark coloured 
skin. Demographic, anthropometric and clinical char-
acteristics of all 245 patients, and stratified to vitamin 
D level are presented in Table  1. The mean age of the 
patients was 67  ±  8  years and 64% were male, with a 
median diabetes duration of 6.0 (3.0–8.0) years. Overall 
mean serum 25(OH)D was 60.3 ± 23.4 nmol/l and mean 
skin autofluorescence 2.64  ±  0.6. Vitamin D deficiency 
(serum 25(OH)D <50 nmol/l) was present in 89 patients 
(37%), 96 patients (39%) had a serum 25(OH)D level 
between 50–74 nmol/l and 60 patients (24%) had a serum 
25(OH)D >75 nmol/l.
Skin autofluorescence values were significantly higher 
in the vitamin D deficient group compared to the group 
with a serum 25(OH)D >75  nmol/l (2.81  ±  0.6 versus 
2.41 ± 0.5; p < 0.001). Skin autofluorescence significantly 
raised with increasing age (2.44 ± 0.49 to 2.91 ± 0.61 in 
patients aged <60 and >70  years, respectively, data not 
shown). No difference in skin autofluorescence was seen 
in patients treated with metformin (n = 225) compared 
to patients without metformin treatment (n = 20) (data 
not shown).
Linear regression analyses were performed to determine 
the association between serum 25(OH)D and skin autoflu-
orescence. A significant association between serum 25(OH)
D and skin autofluorescence (β  =  −0.007; p  <  0.01) was 
demonstrated. Confounders for this association were age, 
ethnicity, season, sun exposure, diabetes duration, presence 
of cardiovascular disease, eGFR, alkaline phosphatase and 
LDL cholesterol. No effect of HbA1c, sex, smoking behav-
iour or the use of statins and/or antihypertensive drugs was 
measured on the association between serum 25(OH)D and 
skin auto fluorescence. After adjustment for above men-
tioned confounding risk factors, the association between 
serum 25(OH)D and skin autofluorescence remained sta-
tistically significant (β = −0.006; p < 0.01) (Table 2). For the 
complete model see Additional file 1.
In patients with previous cardiovascular disease 
(n  =  67) mean skin autofluorescence was significantly 
higher compared to patients without cardiovascular 
disease (n =  178) (AGEs: 2.79 ±  0.57 and 2.59 ±  0.62; 
p = 0.02, respectively). In patients without previous car-
diovascular disease mean skin autofluorescence was sig-
nificantly higher in patients with a serum 25(OH)D level 
<50 nmol/l compared to patients with a serum 25(OH)D 
level >75 nmol/l (2.77 ± 0.60 and 2.37 ± 0.52; p = 0.003, 
respectively). This result was also seen in patients with 
cardiovascular disease, although this difference was not 
statistically significant (2.94  ±  0.54, and 2.58  ±  0.57 in 
patients with a serum 25(OH)D level <50 and >75 nmol/l; 
p = 0.16, respectively) (Figure 1).
Longitudinal analysis
210 out of 245 (85%) patients completed the trial and 
conducted a skin AGE measurement after 6 months. The 
majority of the excluded patients throughout the study 
had changed their hypoglycemic agents on own initia-
tive or due to an HbA1c level >69  mmol/mol (n  =  19), 
two patients had a serum 25(OH)D <15  nmol/l, one 
patient suffered from new onset urolithiasis, and eight 
patients did not show at their last visit. Serum 25(OH)
D raised from 60.8 to 103.6  nmol/l in the vitamin D 
group (n =  107) (p =  <  0.01) and decreased from 61.0 
to 60.3 nmol/l in the placebo group (n = 103) (p = 0.78). 
Mean skin autofluorescence significantly increased 
(2.63  ±  0.53 to 2.74  ±  0.56; p  =  0.02) in the placebo 
group, whereas in the vitamin D group mean skin auto-
fluorescence increased less profoundly which was not sig-
nificant (2.67 ± 0.64 to 2.73 ± 0.69; p = 0.19). Comparing 
the change in mean skin autofluorescence from baseline 
to 6 months, no significant difference was found between 
both groups (β −0.05, 95% CI −0.17 to 0.08, p = 0.47). 
No significant change over time in HbA1c was seen in the 
intervention group whereas mean BMI increased signifi-
cantly (Table 3).
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Table 1 Baseline demographic and clinical characteristics
All Serum 25 (OH)D 
15–49 nmol/l
Serum 25 (OH)D 
50–74 nmol/l
Serum 25 (OH)D 
75–150 nmol/l
p value
N 245 89 96 60
Male (%) 156 (63) 49 (55) 66 (69) 41 (68) 0.09
Age (years) 67 ± 8 67 ± 9 67 ± 9 67 ± 7 0.82
White skin colour (%) 234 (95) 80 (90) 93 (97) 60 (100) 0.01
Diabetes duration (years) 6.0 (3.0–8.0) 5.0 (3.5–7.0) 6.0 (3.0–8.0) 6.0 (3.0–8.0) 0.59
Antidiabetic treatment
 Lifestyle adjustments 11 (5) 5 (6) 4 (4) 2 (3) 0.55
 Metformin 155 (63) 50 (56) 62 (65) 43 (72)
 SU‑derivative 9 (4) 3 (3) 4 (4) 2 (3)
 Metformin + SU‑derivative 70 (28) 31 (35) 26 (27) 13 (22)
DM‑complications (%)
 Retinopathy 11 (5) 5 (6) 4 (4) 2 (3) 0.80
 Neuropathy 32 (13) 11 (12) 11 (12) 10 (17) 0.63
 Microalbuminuria 30 (12) 16 (18) 9 (9) 5 (8) 0.13
Antihypertensive drugs (%)
 Diuretics 88 (36) 38 (42) 28 (30) 22 (37) 0.20
 Calcium channel blockers 44 (18) 19 (21) 14 (15) 11 (18) 0.53
 ACE inhibitors/AT‑II receptor  
antagonists
135 (55) 56 (63) 45 (47) 34 (57) 0.34
 Beta blockers 92 (38) 35 (39) 35 (37) 22 (37) 0.95
Statins (%) 205 (84%) 75 (83%) 80 (84%) 50 (83%) 0.99
Cardiovascular disease (%) 67 (27) 23 (26) 32 (33) 12 (20) 0.16
Smoking status
 Current (%) 36 (15) 17 (19) 12 (12) 7 (12) 0.20
Alcohol use (%) ≤2 units/day 216 (89) 75 (83) 84 (88) 66 (92) 0.03
Exposure to sun
 <5 h/week 102 (42) 51 (57) 36 (37.5) 15 (25) <0.001
 5–10 h/week 103 (42) 33 (37) 45 (47.9) 25 (42)
 >10 h/week 40 (16) 5 (6) 15 (15.6) 20 (33)
Physical activity
 <2 h/week 78 (32) 38 (43) 30 (31) 10 (17) 0.03
 2–5 h/week 112 (45) 38 (43) 46 (48) 28 (47)
 >5 h/week 55 (23) 13 (14) 20 (21) 22 (36)
Season of blood collection
 Spring 24 (10) 10 (11) 11 (11) 3 (5) 0.047
 Summer 66 (27) 16 (18) 24 (25) 26 (43)
 Autumn 119 (48) 48 (54) 45 (47) 26 (43)
 Winter 36 (15) 15 (17) 16 (17) 5 (9)
Body mass index (kg/m2) 28.8 ± 4.5 29.9 ± 4.4 28.0 ± 4.6 28.2 ± 3.9 0.009
WTH ratio 0.98 (0.93–1.04) 0.99 (0.92–1.04) 0.97 (0.93–1.04) 1.00 (0.94–1.03) 0.77
AGE‑value 2.64 ± 0.6 2.81 ± 0.6 2.63 ± 0.6 2.41 ± 0.5 <0.001
Fasting glucose (mmol/l) 7.5 (6.9–8.2) 7.4 (6.9–8.2) 7.5 (6.9–8.6) 7.7 (6.9–8.4) 0.84
Fasting insulin (mU/l) 14.5 (9.0–21.0) 14.9 (9.5–21.8) 13.8 (8.8–21.0) 14.6 (8.7–20.9) 0.78
HbA1c (mmol/mol) 51 (47–55) 51 (49–54) 52 (45–56) 51 (46–55) 0.96
HbA1c (%) 6.8 (6.5–7.2) 6.8 (6.6–7.1) 6.9 (6.3–7.3) 6.8 (6.4–7.2) 0.96
LDL‑cholesterol (mmol/l) 2.5 ± 0.9 2.5 ± 1.0 2.5 ± 1.0 2.4 ± 0.7 0.77
eGFR (ml/min/1.73 m2) 81 ± 18 82 ± 20 81 ± 17 82 ± 17 0.94
Calcium (mmol/l) 2.33 ± 0.08 2.32 ± 0.08 2.33 ± 0.08 2.34 ± 0.07 0.22
Albumine (g/l) 40 (38–41) 39 (38–41) 40 (38–41) 40 (39–41) 0.07
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Discussion
We found a significant inverse association between 
serum 25(OH)D and skin autofluorescence independ-
ent of major confounders, including age, season, diabetes 
duration and renal function in a group of patients with 
relatively tight controlled T2DM. For each 10  nmol/l 
increment in serum 25(OH)D level skin autofluorescence 
decreases with 0.06 in patients with T2DM. Patients with 
a serum 25(OH)D <50 nmol/l had a significantly higher 
skin autofluorescence compared to patients with an ade-
quate serum 25(OH)D level >75 nmol/l (2.81 ± 0.6 and 
2.41 ±  0.5, respectively). Six months of vitamin D sup-
plementation did not alter the amount of skin auto fluo-
rescence significantly compared to the placebo group. 
However, the duration of the intervention could be too 
short for this outcome measure, as skin AGEs have a 
mean half live of 10–15 years [35].
Table 1 continued
All Serum 25 (OH)D 
15–49 nmol/l
Serum 25 (OH)D 
50–74 nmol/l
Serum 25 (OH)D 
75–150 nmol/l
p value
Serum 25(OH)D (nmol/l) 60.3 ± 23.4 36.9 ± 8.0 61.5 ± 7.2 92.9 ± 13.4 <0.001
PTH (pmol/l) 5.1 (4.0–6.8) 5.2 (4.4–7.0) 5.4 (4.1–6.9) 4.3 (3.6–5.9) 0.01
AP (U/l) 72.6 ± 20.6 74.6 ± 24.0 70.1 ± 19.3 73.3 ± 16.6 0.38
Data are presented as numbers (%), mean ± SD or median (ICR).
25(OH)D 25‑hydroxyvitamin D, ACE angiotensin‑converting enzyme, AGE advanced glycation endproduct, AP alkaline phosphatase, AT-II angiotensin II, DM diabetes 
mellitus, eGFR estimated glomerular filtration rate, PTH parathyroid hormone, SU-derivatives sulphonyl‑urea derivatives, T-chol/HDL ratio total cholesterol–high density 
lipoprotein ratio.
Table 2 Linear regression analysis of serum 25(OH)D (independent variable) and skin auto fluorescence (dependent vari-
able)
25(OH)D 25‑hydroxyvitamin D, AGE advanced glycation end product, AP alkaline phosphatase, BMI body mass index, CVD cardiovascular disease, LDL low density 
lipoprotein.
β (95% CI) SE B p value
Model 1: crude analysis −0.007 (−0.010 to −0.004) 0.002 <0.01
Model 2: Model 1 + age, ethnicity, season, smoking, BMI −0.007 (−0.010 to −0.004) 0.002 <0.01
Model 3: Model 2 + sun exposure, diabetes duration, CVD, HbA1c, eGFR, AF, LDL cholesterol −0.006 (−0.009 to −0.003) 0.002 <0.01
Figure 1 Mean skin autofluorescence in vitamin D subgroups 
stratified by cardiovascular disease. 25OHD 25‑hydroxyvitamin D, AGE 
advanced glycation endproducts, CVD cardiovascular disease.
Table 3 Comparison of the main outcomes before and after intervention between both groups
25(OH)D 25‑hydroxyvitamin D, AGE advanced glycation end product, BMI body mass index.
Variable Vitamin D group (n = 107) Placebo group (n = 103) β (95% CIs) p value
0 month 6 months 0 month 6 months
Serum 25(OH)D (nmol/l) 60.8 ± 23.0 103.6 ± 25.7 61.0 ± 23.4 60.3 ± 26.5 42.5 (35.8–49.6) <0.01
AGE‑value 2.67 ± 0.64 2.73 ± 0.69 2.63 ± 0.53 2.74 ± 0.56 −0.05 (−0.17 to 0.08) 0.47
BMI (kg/m2) 28.8 ± 4.8 29.1 ± 4.4 28.7 ± 4.7 28.8 ± 4.8 0.23 (0.01–0.46) 0.04
HbA1c (mmol/mol) 51.1 ± 6.0 50.0 ± 6.3 50.3 ± 5.3 49.4 ± 6.2 1.2 (−0.1 to 2.6) 0.07
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A possible underlying mechanism for the association 
found between skin AGEs and vitamin D status, could be 
a reduction of oxidative stress by vitamin D and thereby 
a decrease in the formation of AGEs and pro-inflamma-
tory cytokines that mediate microvascular and macro-
vascular complications in T2DM. A recent in vitro study 
demonstrated a decrease of cytokine-mediated endothe-
lial inflammation after addition of calcitriol, supporting 
the concept that calcitriol may act as a vascular protec-
tive agent counteracting the probable deleterious actions 
of AGEs on endothelial cell activities [13, 36]. Moreover, 
several studies have shown protective effects of vita-
min D on vascular wall function and cell membranes by 
maintaining steady levels of certain intracellular antioxi-
dants, by reducing lipid peroxidation and by reducing the 
overproduction of reactive oxygen species [37]. A recent 
study performed by Stürmer et al. [38] among 119 healthy 
en 27 hypertensive non-diabetic participants with a mean 
serum 25(OH)D 56.2 ± 22.2 nmol/l, revealed no associa-
tion between vitamin D status and skin autofluorescence.
Our results regarding the significantly higher skin 
autofluorescence found in patients with previous cardio-
vascular disease compared to patients without cardiovas-
cular disease (mean skin autofluorescence: 2.79  ±  0.57 
versus 2.59  ±  0.62) are in line with previous studies 
which demonstrated mean skin autofluorescence values 
of 2.57 in patients with T2DM without diabetes-related 
complications, and skin AGEs of 3.12, 2.91 and 2.71 in 
patients with T2DM and both micro- and macrovascular 
complications, solely macrovascular complications and 
solely microvascular complications, respectively [7].
Interestingly, the patients in the highest vitamin D 
group in our study had a mean skin autofluorescence 
comparable with the non-diabetic population demon-
strated in a study by Koetsier et  al. [39]. The authors 
generated a formula for calculating the mean skin auto-
fluorescence in the general population without diabetes 
mellitus: 0.024 × age + 0.83. When this formula is applied 
to our study population with a mean age of 67 years, the 
calculated mean skin autofluorescence is 2.44. In our 
study results the patients with T2DM in the highest vita-
min D group had a lower mean autofluorescence level: 
2.41 ± 0.5. This could imply a protective effect of vitamin 
D on the formation and accumulation of AGEs in patients 
with T2DM. However, an important limitation in our 
study is that we measured the accumulated AGEs in the 
skin using an AGE-reader, and other known AGE types, 
such as circulating AGEs and AGEs without fluorescent 
properties could have provided different results within the 
vitamin D subgroups. In addition from this point of view 
the association between vitamin D status and skin auto-
fluorescence found in our study could be explained by the 
fact that in theory cutaneous AGE accumulation could 
hinder the photoconversion of the provitamin D into vita-
min D. Nevertheless, our results show that vitamin D suf-
ficiency is mainly found in patients with T2DM without 
high cardiovascular risk profile as indicated by the age-
adjusted AGE levels within the normal range. Further-
more, we plan to conduct future analyses with the stored 
serum of all patients to measure circulating AGEs.
In contrast to previous studies, smoking was not cor-
related to skin autofluorescence in our study. This may be 
due to the small group of smokers in our study population 
(n = 36; 15%). HbA1c, which is also an end product of gly-
cation, was not associated with skin autofluorescence. This 
is not surprisingly as earlier research demonstrated only a 
weak effect between skin autofluorescence and HbA1c. A 
logical explanation is that HbA1c represents AGE accu-
mulation over a short period of approximately 6–8 weeks, 
while skin AGEs accumulate over 10–15 years [35].
In conclusion, this preliminary report demonstrates an 
independent association between vitamin D status and 
skin autofluorescence in patients with tight controlled 
T2DM. A short intervention of vitamin D supplementa-
tion, however did not have any effect on the amount of 
skin autofluorescence. Future research should focus on 
measuring circulating AGEs after a longer follow-up and 
treatment with vitamin D.
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